Minister of Health and Welfare Award for Contributions to Health and Medical Technology Promotion, Jang Yeong-sil Technology Innovation Award

IMBiologics (CEO: Kyung-Sik Ha) announced on the 4th that it was awarded the Minister of Trade, Industry, and Energy Award as an 'Outstanding Biohealth R&D Company' at the 2024 Bioindustry Day event held on the 28th of last month at the Westin Chosun Hotel in Seoul.

This award recognizes outstanding research and development (R&D) companies that have contributed to the advancement of the biohealth sector and the growth of K-Bio. The selection process evaluates companies based on their major achievements throughout the year to motivate and promote further development in the industry.

A company representative stated, "The IMB-101 pipeline, a dual antibody for the treatment of autoimmune diseases, is the first of its kind in South Korea to undergo clinical trials in the U.S. and has been selected as an outstanding project in the National New Drug Development Program." They also mentioned that the company had successfully signed two global technology transfer agreements with Navigator Medicines in the U.S. in June and with Hangzhou Zhongmei Huadong Pharmaceutical in China in August.

On the same day, IMBiologics was also honored at the 2024 Health Industry Performance Exchange Conference held at the Four Seasons Hotel in Seoul. CEO Kyung-Sik Ha was recognized for his contributions to the development of the health industry and received the Minister of Health and Welfare Award for Contributions to Health and Medical Technology Promotion (R&D). Additionally, the company was awarded the Minister’s Award for Technological Innovation at the 105th IR52 Jang Yeong-sil Award ceremony, organized by the Ministry of Science and ICT.

CEO Kyung-Sik Ha expressed his delight, stating, “As we approach the end of the year, I am pleased to have our R&D achievements recognized by various government departments. We will continue to focus on advancing research and development to contribute to the growth of the bio industry.”

"Reporter Dae-Yeol Nam (dynam@hitnews.co.kr)"